X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the termination, Neurimmune regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid, for the treatment and prevention of Alzheimer’s disease.
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $380.0 million Upfront Cash: Undisclosed
Deal Type: Termination January 31, 2024
Details:
NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis and strengthens the Company’s broader commitment to addressing cardiomyopathies that can lead to heart failure (HF).
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: $760.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration March 01, 2022
Details:
In the new collaboration, companies aim to generate and validate human-derived monoclonal antibodies (NI504) against Ono’s selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from collaboration.
Lead Product(s): Human-derived Monoclonal Antibodies
Therapeutic Area: Neurology Product Name: NI504
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2022
Details:
Under the agreement, Alexion will be granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. NI006, an ATTR depleter, a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis.
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: $760.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration January 07, 2022
Details:
The data of three separate clinical studies unequivocally show that aducanumab’s biological activity removed amyloid from brains of patients with Alzheimer’s disease.
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: Aduhelm
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Lead Product(s): NI007
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ethris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2020
Details:
Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of NI006 in patients with wild-type and hereditary forms of ATTR cardiomyopathy.
Lead Product(s): NI006
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
